company background image
LUP logo

Luye Pharma Group DB:LUP Stock Report

Last Price

€0.26

Market Cap

€992.2m

7D

-10.5%

1Y

-37.9%

Updated

22 Dec, 2024

Data

Company Financials +

Luye Pharma Group Ltd.

DB:LUP Stock Report

Market Cap: €992.2m

LUP Stock Overview

An investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. More details

LUP fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance4/6
Financial Health4/6
Dividends0/6

Rewards

Price-To-Earnings ratio (9.8x) is below the German market (15.3x)

Earnings are forecast to grow 14.36% per year

Earnings grew by 68.3% over the past year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 58.7%

Risk Analysis

No risks detected for LUP from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Luye Pharma Group Ltd. Competitors

Dermapharm Holding

XTRA:DMP

€2.0b

PharmaSGP Holding

XTRA:PSG

€283.0m

Pierrel

DB:2FJ0

€92.8m

MPH Health Care

DB:93M1

€95.9m

Price History & Performance

Summary of share price highs, lows and changes for Luye Pharma Group
Historical stock prices
Current Share PriceHK$0.26
52 Week HighHK$0.43
52 Week LowHK$0.26
Beta0.86
1 Month Change-16.34%
3 Month Change-24.71%
1 Year Change-37.86%
3 Year Change-33.68%
5 Year Change-62.07%
Change since IPO-62.57%

Recent News & Updates

Recent updates

Shareholder Returns

LUPDE PharmaceuticalsDE Market
7D-10.5%-2.5%-2.6%
1Y-37.9%-15.6%6.9%

Return vs Industry: LUP underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.

Return vs Market: LUP underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is LUP's price volatile compared to industry and market?
LUP volatility
LUP Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: LUP has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: LUP's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19945,234Dian Bo Liuwww.luye.cn

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Apleek Transdermal Patch for contraception; Rivastigmine Transdermal Patch for the treatment of Alzheimer’s disease; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders.

Luye Pharma Group Ltd. Fundamentals Summary

How do Luye Pharma Group's earnings and revenue compare to its market cap?
LUP fundamental statistics
Market cap€992.21m
Earnings (TTM)€101.21m
Revenue (TTM)€829.33m

9.8x

P/E Ratio

1.2x

P/S Ratio

Is LUP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LUP income statement (TTM)
RevenueCN¥6.31b
Cost of RevenueCN¥1.97b
Gross ProfitCN¥4.34b
Other ExpensesCN¥3.57b
EarningsCN¥770.46m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.20
Gross Margin68.73%
Net Profit Margin12.20%
Debt/Equity Ratio66.6%

How did LUP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:20
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Luye Pharma Group Ltd. is covered by 25 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Wai Chak YuenBOCI Research Ltd.
Bo LiBOCOM International Securities Limited